Jagsonpal

Delhi, India Founded: 1964 • Age: 62 yrs Listed
Traditional company manufacturing bulk drugs and finished formulations
Request Access
Report Incorrect Data
Page last updated

About Jagsonpal

Jagsonpal is a publicly listed company based in Delhi (India) founded in 1964. Traditional company manufacturing bulk drugs and finished formulations. The company has 1,410 employees. Jagsonpal has completed 3 acquisitions, including Aequitas Healthcare, Group Pharma and Yash Pharma. Its chief executive, as recorded, is Parveen Kaushal. Its Indian entity Jagson Pal Pharmaceuticals Limited. reported revenue of ₹299 Cr. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.

Company details

Jagsonpal was established in 1964 as a pharmaceutical entity focused on bulk drugs and finished formulations. A portfolio of 9 active pharmaceutical ingredients and over 200 formulation products is maintained. Operations span 13 countries across three continents, in addition to India. Contract manufacturing services are primarily provided to other pharmaceutical firms. The company is headquartered in Delhi, India.

Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹1,397 Cr

    JAGSNPHARM · NSE

  • Share Price
    ₹223.06

    +5.34% today

  • Revenue
    ₹287 Cr

    FY 2025-26 · +6.9% YoY

  • EBITDA
    ₹56.00 Cr

    Margin 19.5%

  • Net Profit
    ₹44.65 Cr

    FY 2025-26 · +41.3% YoY

  • P/E (TTM)
    29.7x

    P/B 5.1x

  • ROE
    16.7%

    ROCE 21.8%

  • Debt / Equity
    0.03

    Interest cover 2.2x

  • Employee Count
    1,410
  • Investments & Acquisitions
    Aequitas Healthcare

    & 2 more

Apps and channels of Jagsonpal

its YouTube channel Jagsonpal Medical Insights has 8.22K subscribers and 30 videos.

Jagsonpal Medical Insights
YouTube 8.22K subscribers 30 videos Howto & Style
Open channel

Videos from Jagsonpal

The most watched videos on Jagsonpal's YouTube channel, Jagsonpal Medical Insights (8.22K subscribers). Click a video to play it here.

Recent ADVANCES in INFERTILITY
711 views
ENDOMETRIOSIS—How to Deal With It INSPIRE & IGNITE SERIES #15
460 views
PREMATURE OVARIAN INSUFFICIENCY INSPIRE & IGNITE SERIES 11
443 views
RPL, RIF and PCOS THE DIFFICULT TRIO - INSPIRE & IGNITE SERIES 17
439 views

More on Jagsonpal Medical Insights.

Board of directors of Jagson Pal Pharmaceuticals Limited. (Jagsonpal)

Jagson Pal Pharmaceuticals Limited. is the primary company behind Jagsonpal. The board of Jagson Pal Pharmaceuticals Limited. currently have 6 directors; the longest-serving is Radhika Madhukar Dudhat, appointed in 2022. 22 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Radhika Madhukar Dudhat
DIN 00016712
Director29 Jun 20224 yrs 3 moJagson Pal Pharmaceuticals Limited.
Harsha Raghavan
DIN 01761512
Director29 Jun 20224 yrs 3 moJagson Pal Pharmaceuticals Limited.
Debasis Bikash Nandy
DIN 06368365
Director29 Jun 20224 yrs 3 moJagson Pal Pharmaceuticals Limited.
Pallavi Dinodia Gupta
DIN 06566637
Director29 Jun 20224 yrs 3 moJagson Pal Pharmaceuticals Limited.
Prithipal Singh Kochhar
DIN 01052194
Director29 Jun 20224 yrs 3 moJagson Pal Pharmaceuticals Limited.
Manish Gupta
DIN 06805265
Managing Director16 Jul 20224 yrs 3 moJagson Pal Pharmaceuticals Limited.

People of Jagsonpal

15 people are tracked at Jagsonpal (8 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 1,410.

NameRoleGroup
Parveen Kaushal
CEOLeadership
Manish Gupta
Managing DirectorLeadership
Sudeep Paul
Vice President Sales MarketingLeadership
Anupam Mallick
Head Of Learning And DevelopmentLeadership
Tirthankar Chatterjee
General Manager Sales MarketingLeadership
S V Subha Rao
CFO & Compliance OfficerLeadership
Satish Kesare
Deputy General Manager MarketingLeadership
Raj Kumar Samal
VP -sales & MarketingLeadership
Radhika M Dudhat
Independent DirectorBoard & advisors
Debasis B Nandy
Independent DirectorBoard & advisors
Pallavi Dinodia Gupta
Independent DirectorBoard & advisors
Prithipal Singh Kochhar
Non-Executive DirectorBoard & advisors
Harsha Raghavan
Non-Executive DirectorBoard & advisors
Abhishek Joshi
Company Secretary & Compliance OfficerTeam
Rajkumar Bera
Senior Area ManagerTeam
Premium access

Complete people profiles for Jagsonpal

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Jagsonpal

Jagsonpal is a publicly listed company on the NSE with ticker symbol JAGSNPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date01 Mar 2000
  • Listed onNSE: JAGSNPHARM
  • Listed entityJagsonpal Pharmaceuticals Ltd.
  • Exchange sectorHealth technology
  • ISININE048B01035
  • Share price₹223.85 (+0.6% on the day) · 2026-10-14
  • Market capitalisation₹1,470 Cr
  • Price to earnings33.4
  • EPS (diluted, trailing year)₹6.70
  • Dividend yield1.12%
  • Volume (last session)51,897

Financials of Jagsonpal

Exchange-reported figures of Jagson Pal Pharmaceuticals Limited., the listed company behind Jagsonpal (NSE: JAGSNPHARM).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹287 Cr
+6.9% YoY
EBITDA
₹56.00 Cr
+18.1% YoY
Profit After Tax
₹44.65 Cr
+41.3% YoY
Net Worth
₹276 Cr
+15.1% YoY
Total Assets
₹286 Cr
+13.8% YoY
Total Debt
₹8.17 Cr
-11.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue287269209237218188159
Revenue growth+6.9%+28.8%-11.8%+8.8%+15.8%+18.5%-
EBITDA56.0047.4123.0630.6925.0119.098.54
EBITDA margin+19.5%+17.6%+11.1%+13.0%+11.5%+10.2%+5.4%
Profit before tax57.5369.8729.8734.8026.6221.889.43
Net profit44.6531.6022.4628.6018.3417.067.91
Net profit margin+15.6%+11.8%+10.8%+12.1%+8.4%+9.1%+5.0%
EPS (₹)6.438.348.5010.207.206.513.00
Balance sheet
Total assets286251197166134129116
Net worth276240187159133122111
Total debt8.179.248.946.000.006.794.66
Cash & bank10612914811525.2560.2338.07
Net working capital11613717913860.3183.6166.75
Cash flow
Cash from operations46.8155.1135.1746.666.9128.2211.25
Cash from investing(35.65)(45.15)(24.55)(57.67)(25.78)(2.26)(10.76)
Cash from financing(12.15)(11.70)(8.91)(0.46)(17.55)(6.83)(0.94)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue82.2364.2072.9574.4775.6158.5674.0374.69
Revenue growth (YoY)+8.8%+9.6%-1.5%-0.3%+23.1%---
Other income2.833.172.983.032.832.7725.511.65
Total expenses64.9953.0458.7658.0361.4050.0658.1958.41
EBITDA17.2411.1614.1916.4414.218.5015.8416.28
EBITDA margin+21.0%+17.4%+19.5%+22.1%+18.8%+14.5%+21.4%+21.8%
Depreciation2.142.322.392.392.352.312.412.34
Interest0.250.250.260.270.250.260.260.23
Profit before tax17.6811.7614.5216.8114.448.7038.6815.36
Tax4.492.993.574.243.642.136.683.91

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue82.2364.2072.9574.4775.6158.5674.0374.69
Revenue growth (YoY)+8.8%+9.6%-1.5%-0.3%+23.1%---
Other income2.833.172.983.032.832.7725.511.65
Total expenses64.9953.0458.7658.0361.4050.0658.1958.41
EBITDA17.2411.1614.1916.4414.218.5015.8416.28
EBITDA margin+21.0%+17.4%+19.5%+22.1%+18.8%+14.5%+21.4%+21.8%
Depreciation2.142.322.392.392.352.312.412.34
Interest0.250.250.260.270.250.260.260.23
Profit before tax17.6811.7614.5216.8114.448.7038.6815.36
Tax4.492.993.574.243.642.136.683.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue287269209237218188159
Revenue growth+6.9%+28.8%-11.8%+8.8%+15.8%+18.5%-
Other income12.0031.559.285.733.434.392.53
Total expenses231221186206193169150
Employee cost70.7470.9362.0965.1857.6853.9850.37
EBITDA56.0047.4123.0630.6925.0119.098.54
EBITDA margin+19.5%+17.6%+11.1%+13.0%+11.5%+10.2%+5.4%
Depreciation9.448.131.661.211.531.091.13
Interest1.030.960.810.410.290.510.51
Profit before tax57.5369.8729.8734.8026.6221.889.43
Tax14.4414.507.418.097.784.821.54
Net profit44.6531.6022.4628.6018.3417.067.91
Net profit margin+15.6%+11.8%+10.8%+12.1%+8.4%+9.1%+5.0%
EPS (₹)6.438.348.5010.207.206.513.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.3913.2813.2213.1013.1013.1013.10
Reserves & surplus26122617414612010997.93
Shareholders' funds (net worth)276240187159133122111
Secured loans0.000.000.000.000.000.00(1.74)
Unsecured loans8.179.248.946.000.006.796.40
Total debt8.179.248.946.000.006.794.66
Total liabilities286251197166134129116
Assets
Gross block10210311.5933.2258.1360.1255.83
Net block85.3194.459.3024.2822.6025.7222.09
Capital work in progress0.000.000.000.000.000.004.25
Investments0.000.000.001.1250.6715.3111.39
Inventories14.6415.2015.0020.6829.7429.7229.33
Sundry debtors17.1913.1810.9520.8715.5812.6621.45
Cash & bank balances10612914811525.2560.2338.07
Loans & advances5.134.0822.908.3916.7114.616.06
Total current assets14316119716587.2811794.91
Total current liabilities26.7224.2917.7526.8226.9733.6128.16
Net working capital11613717913860.3183.6166.75
Total assets286251197166134129116
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.0312.7611.0522.5358.9439.8138.53
Net cash from operating activities46.8155.1135.1746.666.9128.2211.25
Net cash from investing activities(35.65)(45.15)(24.55)(57.67)(25.78)(2.26)(10.76)
Net cash from financing activities(12.15)(11.70)(8.91)(0.46)(17.55)(6.83)(0.94)
Net change in cash(0.99)(1.73)1.71(11.47)(36.42)19.13(0.46)
Closing cash10612914811525.2560.2338.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.9%+28.8%-11.8%+8.8%+15.8%+18.5%-
EBITDA growth+18.1%+105.6%-24.9%+22.7%+31.0%+123.5%-
PBT growth-17.7%+133.9%-14.2%+30.7%+21.7%+132.0%+4.8%
Net income growth+41.3%+40.7%-21.5%+55.9%+7.5%+115.7%-
Revenue CAGR (3Y)+6.7%+7.3%+3.6%+14.3%+9.3%+14.1%+3.3%
EBITDA CAGR (3Y)+22.2%+23.8%+6.5%+53.2%+38.9%-+14.0%
Profitability & leverage
Net income margin+15.0%+20.6%+10.8%+11.3%+8.7%+9.1%+5.0%
Return on capital employed+21.8%+22.8%+16.9%+23.5%+21.1%+19.6%+9.5%
Return on net worth+16.7%+14.8%+13.0%+18.3%+15.3%+15.7%+7.9%
Debt / equity0.030.040.040.020.030.050.04
Long-term debt / equity0.030.040.040.020.000.000.00
Interest cover2.212.443.791.391.242.836.88
Efficiency & per share
Fixed asset turnover2.804.689.315.183.943.753.33
Inventory turnover19.2517.8011.709.397.326.375.11
Debtors turnover18.9222.2713.1212.9915.4111.027.52
EPS (₹)6.438.348.5010.207.206.513.00
Dividend per share (₹)4.002.505.005.004.001.000.50
Book value per share (₹)41.0136.0870.8860.6550.6843.5539.39

Investments & Acquisitions by Jagsonpal

Jagsonpal has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aequitas Healthcare, Group Pharma and Yash Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Group Pharma
Manufactures specialized oral care and healthcare products for consumers and partners worldwide.
grouppharma.comMumbai, India1980Sep 2026••••
Aequitas Healthcare
Distributor of medical products
aequitashealthcare.comMumbai, India2017Jun 2026••••
Yash Pharma
Architect providing design and construction services for residential projects
yashpharma.comMumbai, India1972Jun 2024••••
Premium access

Complete acquisition details for Jagsonpal

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Jagsonpal

5 dated milestones of Jagsonpal across 62 years, from founding to its latest funding, stage changes and deals.

  1. Founded Jagsonpal is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Yash Pharma.
  4. Acquisition Acquires Aequitas Healthcare.
  5. Acquisition Acquires Group Pharma.

Similar companies to Jagsonpal

Jagsonpal has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed similar companies of Jagsonpal

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Jagsonpal

The website of Jagsonpal (jagsonpal.com) receives about 9.1K visits a month and ranks #2,185,585 among all websites worldwide, #2,998 in Pharmacy.

  • Monthly visits
    9.1K

    ▼ 5.5% vs previous month

  • Unique visitors
    4.7K

    per month

  • Global rank
    #2,185,585

    among all websites

  • Category rank
    #2,998

    Health · Pharmacy

Similar websites

Websites whose visitors overlap most with Jagsonpal. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Incepta Pharmaceuticals
inceptapharma.com
100%
#657,683View details
Synokem Pharma
synokempharma.com
88%
1.8K#7,667,368View details
Olympus Medical
olympusmedical.co.in
87%
1.7K#8,902,755View details
MedPlusMart
medplusmart.com
76%
1.9M#27,494View details
Alchem International
alcheminternational.com
71%
13.4K#6,011,638View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 17 similar websites and full traffic analytics for Jagsonpal

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 17 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Jagsonpal (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Jagsonpal

Jagsonpal, BlueBinaries, and Macquarie's Blueleaf Ink Multiple M&A Deals
VCCircle • 1 month ago
Jagsonpal Pharmaceuticals to acquire Group Pharmaceuticals' wellness portfolio for up to Rs 46.7 crore
MergersIndia • 1 month ago
Jagsonpal Pharmaceuticals: Purchases Wellness Segment Of Group Pharmaceuticals For Up To ₹46.7 Crore Through Slump Sale.
Exchange Update • 1 month ago
Jagsonpal Pharmaceuticals Q4FY26 Results: Net profit up 19%, 200% dividend
Scanx • 2 months ago
JAGSNPHARM: Q1 FY27 delivered robust growth, margin expansion, and strategic hospital segment entry
Quartr • 2 months ago
JAGSNPHARM: Q1FY27 delivered double-digit profit growth, margin expansion, and strategic acquisition-led scale
Quartr • 3 months ago
JAGSNPHARM: Revenue and profit grew, with buy-back, ESOPs, and acquisition marking a dynamic quarter
Quartr • 3 months ago
JAGSNPHARM: Q4 FY 2026 saw double-digit growth, margin expansion, and strong shareholder returns
Quartr • 6 months ago
JAGSNPHARM: 7% revenue growth, 19% PAT rise, robust cash, and strategic buyback drive strong FY26 results
Quartr • 6 months ago
JAGSNPHARM: FY26 saw 7% revenue growth, 19% profit rise, and major shareholder returns via dividend and buyback
Quartr • 6 months ago
Premium access

Complete news archive for Jagsonpal

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jagsonpal

Jagsonpal was founded in 1964.

Jagsonpal is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

Parveen Kaushal is the CEO of Jagsonpal, as recorded in our data.

Jagsonpal has 1,410 employees.

The primary company behind Jagsonpal, Jagson Pal Pharmaceuticals Limited., reported revenue of ₹299 Cr for FY 2026, up 7% year on year.

Jagsonpal was established in 1964 as a pharmaceutical entity focused on bulk drugs and finished formulations. A portfolio of 9 active pharmaceutical ingredients and over 200 formulation products is maintained. Operations span 13 countries across three continents, in addition to India. Contract manufacturing services are primarily provided to other pharmaceutical firms. The company is headquartered in Delhi, India.

Jagsonpal's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Yes, Jagsonpal is publicly traded on NSE under the ticker symbol JAGSNPHARM.

Jagsonpal has made 3 acquisitions, including Aequitas Healthcare, Group Pharma, and Yash Pharma.

Jagsonpal operates through Jagson Pal Pharmaceuticals Limited..

The legal entities of Jagsonpal currently have 8 directors, including Radhika Madhukar Dudhat, Harsha Raghavan, Debasis Bikash Nandy and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available